Safety and activity of alflutinib in patients with advanced EGFR T790M mutation non-small cell lung cancer who progressed after EGFR-TKI therapy

被引：0
|
作者：
Shi, Y-K. [1 ]
Zhang, S. [2 ]
Hu, X. [1 ]
Feng, J. [3 ,14 ]
Ma, Z. [4 ]
Zhou, J. [5 ]
Yang, N. [6 ]
Wu, L. [7 ]
Liao, W. [8 ]
Han, X. [9 ]
Wang, Z. [10 ]
Zhang, X. [11 ]
Qin, S. [12 ]
Ying, K. [13 ]
Feng, J. [3 ,14 ]
Fang, J. [10 ]
Liu, L. [15 ]
Jiang, Y. [16 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Canc, Dept Med Oncol,Natl Canc Ctr, Beijing, Peoples R China
[2] Capital Med Univ, Beijing Chest Hosp, Dept Oncol, Beijing, Peoples R China
[3] Jiangsu Canc Hosp, Dept Med Oncol, Nanjing, Jiangsu, Peoples R China
[4] Henan Prov Canc Hosp, Dept Resp Med, Zhengzhou, Henan, Peoples R China
[5] Zhejiang Univ, Affiliated Hosp 1, Dept Resp Med, Coll Med, Hangzhou, Zhejiang, Peoples R China
[6] Hunan Canc Hosp, Dept Pulm Oncol, Changsha, Hunan, Peoples R China
[7] Hunan Canc Hosp, Dept Gastroenterol, Changsha, Hunan, Peoples R China
[8] Nanfang Med Univ, Nanfang Hosp, Dept Med Oncol, Guangzhou, Guangdong, Peoples R China
[9] Chinese Acad Med Sci & Peking Union Med Coll, Dept Med Oncol, Beijing Key Lab Clin Study Anticanc Mol Targeted, Natl Canc Ctr,Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China
[10] Peking Univ, Dept Pulm Oncol, Canc Hosp, Beijing, Peoples R China
[11] Nantong Tumor Hosp, Dept Med Oncol, Nantong, Peoples R China
[12] Nanjing Univ Chinese Med, Med Oncol, PLA Canc Ctr, Bayi Hosp, Nanjing, Jiangsu, Peoples R China
[13] Zhejiang Univ, Sch Med, Dept Resp Med, Sir Run Run Shaw Hosp, Hangzhou, Zhejiang, Peoples R China
[14] Nantong Univ, Dept Resp Med, Affiliated Hosp, Nantong, Peoples R China
[15] Huazhong Univ Sci & Technol, Union Hosp, Dept Thorac Oncol, Tongji Med Coll,Canc Ctr, Wuhan, Peoples R China
[16] Shanghai Allist Pharmaceut Inc, Clin Affairs & Regulatory Dept, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1531P
引用
收藏
页码：629 / 629
页数：1
相关论文
共 50 条
  • [31] The Impact of Acquired EGFR T790M Mutation and EGFR Circulating Cell-Free DNA on Survival in Patients with Lung Adenocarcinoma Following EGFR-TKI Therapy
    Cheng, Wen-Chien
    Hsia, Te-Chun
    Tu, Chih-Yen
    Chen, Hung-Jen
    ONCOTARGETS AND THERAPY, 2020, 13 : 13425 - 13435
  • [32] Australian recommendations for EGFR T790M testing in advanced non-small cell lung cancer
    John, Thomas
    Bowden, Jeffrey J.
    Clarke, Stephen
    Fox, Stephen B.
    Garrett, Kerryn
    Horwood, Keith
    Karapetis, Christos S.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 (04) : 296 - 303
  • [33] Analysis of Acquired EGFR T790M Mutation in Patients with Non-Small Cell Lung Cancer Who Received Icotinib Progress
    Huang, R.
    Xu, C.
    Wang, W.
    Li, J.
    He, C.
    Zhu, Y.
    Zhuang, W.
    Huang, Z.
    Chen, Y.
    Chen, G.
    Fang, M.
    Lv, T.
    Song, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S882 - S882
  • [34] Efficacy and Safety Data of Osimertinib in Elderly Patients with NSCLC Who Harbor the EGFR T790M Mutation After Failure of Initial EGFR-TKI Treatment
    Furuta, Hiromi
    Uemura, Takehiro
    Yoshida, Tatsuya
    Kobara, Makiko
    Yamaguchi, Teppei
    Watanabe, Naohiro
    Shimizu, Junichi
    Horio, Yoshitsugu
    Kuroda, Hiroaki
    Sakao, Yukinori
    Yatabe, Yasushi
    Hida, Toyoaki
    ANTICANCER RESEARCH, 2018, 38 (09) : 5231 - 5237
  • [35] Risk Factors for Developing T790M Mutation in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer
    Ouyang, W.
    Xie, C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E526 - E526
  • [36] Efficacy and safety of apatinib plus EGFR-TKI in advanced non-small cell lung cancer with EGFR-TKI resistance (date updated)
    Tian, R.
    Guo, W.
    Guo, Y.
    Zhang, X.
    Zhu, H.
    Shen, F.
    Zhang, X.
    Wang, R.
    Ren, X.
    Li, J.
    Song, X.
    ANNALS OF ONCOLOGY, 2020, 31 : S873 - S873
  • [37] Neoadjuvant EGFR-TKI therapy in Non-Small cell lung cancer
    Grant, Christopher
    Nagasaka, Misako
    CANCER TREATMENT REVIEWS, 2024, 126
  • [38] Targeting the EGFR T790M mutation in non-small-cell lung cancer
    Normanno, Nicola
    Maiello, Monica Rosaria
    Chicchinelli, Nicoletta
    Iannaccone, Alessia
    Esposito, Claudia
    De Cecio, Rossella
    D'alessio, Amelia
    De Luca, Antonella
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2017, 21 (02) : 159 - 165
  • [39] Clinicopathological Characteristics of Non-small Cell Lung Cancer Patients With Primary Concomitant EGFR T790M Mutation
    Li, Hang
    Wang, Rui
    Hu, Haichuan
    Pan, Yunjian
    Wang, Lei
    Zhang, Yang
    Sun, Yihua
    Chen, Haiquan
    CHEST, 2014, 145 (03)
  • [40] The Feasibility of Interventional Pulmonology Methods for Detecting the T790M Mutation after the First or Second-Generation EGFR-TKI Resistance of Non-Small Cell Lung Cancer
    Cheng, Wen-Chien
    Shen, Yi-Cheng
    Chen, Chieh-Lung
    Liao, Wei-Chih
    Chen, Hung-Jen
    Hsia, Te-Chun
    Chen, Chia-Hung
    Tu, Chih-Yen
    DIAGNOSTICS, 2023, 13 (01)
12345